Adhesive patch for transdermal drug delivery
This article was originally published in Start Up
Medherant Ltd. 's drug delivery patch technology can accommodate medium or low potency drugs at a suitable saturation level to permeate the skin but without compromising adhesion, which existing patch technology has failed to achieve. This means that low potency drugs such as ibuprofen – the company's first product – can now be formulated into a patch rather than only being available in topical gel or cream.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
Israeli-based start-up Tyto Care markets TytoHome, a device that allows consumers to check their ears, breathing and temperature from home and share the findings with a clinician for remote diagnosis.
The race continues to heat up in the bioprinting space over which players will first reach the finish line in gaining approval for tissue and organ replacements. Research organizations and companies worldwide are in various states of development for these milestones in regenerative medicine, ranging from bioprinting skin to a mini human heart. But regulatory hurdles and quality testing could be formidable.